Literature DB >> 16443944

Diagnostic, treatment, and demographic factors influencing survival in a population-based study of adult glioma patients in the San Francisco Bay Area.

Margaret Wrensch1, Terri Rice, Rei Miike, Alex McMillan, Kathleen R Lamborn, Kenneth Aldape, Michael D Prados.   

Abstract

We compare survival estimates for population-based glioma cases by using two diagnostic coding schemes, (1) the International Classification of Diseases, Oncology, second edition (ICD-O-2) as reported by the Surveillance, Epidemiology, and End Results (SEER) program and (2) central neuropathology review diagnosis based on the World Health Organization II classification. In addition, among review categories, we estimate survival in relation to several patient demographic and treatment factors. Eligible cases included adults residing in the San Francisco Bay SEER Area with newly diagnosed, histologically confirmed glioma during the years 1991-1994 and 1997-1999. The study group included participating subjects for whom subsequent central neuropathology review confirmed glioma. We determined treatments, vital status, and other factors by using registry, interview, medical record, and active follow-up data. Survival differences between anaplastic astrocytoma (AA) and astrocytoma were apparent from review diagnoses (median months of survival for AA, 13.0 [95% CI, 9.9-19.5], and astrocytoma, 101.3 [95% CI lower limit, 42.1; upper limit not yet reached]), but not with ICD-O-2 diagnoses reported by SEER (median months of survival for AA, 16.6 [95% CI, 12.0-20.7], and astrocytoma, not otherwise specified, 17.2 [95% CI, 10.6-71.6]). This finding emphasizes the need for improvements in coding for nonglioblastoma astrocytomas to provide better population survival estimates. When review diagnosis was used, younger age and resection (vs. biopsy) were statistically significant for all histology groups analyzed by multivariable Cox proportional hazard models. Additional statistically significant variables were as follows: among 517 glioblastoma patients, radiation treatment and being married; among 105 AA patients, inclusion of chemotherapy in the initial treatment; and among 106 patients with nonanaplastic oligodendroglial tumors, college education. Further consideration of impact of marital status, education, and other social factors in glioma survival may be warranted.

Entities:  

Mesh:

Year:  2006        PMID: 16443944      PMCID: PMC1871921          DOI: 10.1215/S1522851705000268

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   12.300


  45 in total

1.  A comparative survival evaluation and assessment of interclassification concordance in adult supratentorial astrocytic tumors.

Authors:  A K Karak; R Singh; P N Tandon; C Sarkar
Journal:  Pathol Oncol Res       Date:  2000       Impact factor: 3.201

2.  Patterns of expression of Rb and p16 in astrocytic gliomas, and correlation with survival.

Authors:  V K Puduvalli; A P Kyritsis; K R Hess; M L Bondy; G N Fuller; G P Kouraklis; V A Levin; J M Bruner
Journal:  Int J Oncol       Date:  2000-11       Impact factor: 5.650

3.  Gamma-ray mutagen sensitivity and survival in patients with glioma.

Authors:  A J Sigurdson; M L Bondy; K R Hess; S A Toms; A P Kyritsis; J Gu; L E Wang; X Wang; P Adatto; J L Bruner; W K Yung; V A Levin; Q Wei
Journal:  Clin Cancer Res       Date:  1998-12       Impact factor: 12.531

4.  Differential expression of MMAC/PTEN in glioblastoma multiforme: relationship to localization and prognosis.

Authors:  T Sano; H Lin; X Chen; L A Langford; D Koul; M L Bondy; K R Hess; J N Myers; Y K Hong; W K Yung; P A Steck
Journal:  Cancer Res       Date:  1999-04-15       Impact factor: 12.701

Review 5.  What causes childhood brain tumors? Limited knowledge, many clues.

Authors:  G Bunin
Journal:  Pediatr Neurosurg       Date:  2000-06       Impact factor: 1.162

6.  Survival rates for primary malignant brain tumours in Europe. EUROCARE Working Group.

Authors:  M Sant; G van der Sanden; R Capocaccia
Journal:  Eur J Cancer       Date:  1998-12       Impact factor: 9.162

7.  Allelic deletion analyses of MMAC/PTEN and DMBT1 loci in gliomas: relationship to prognostic significance.

Authors:  H Lin; M L Bondy; L A Langford; K R Hess; G L Delclos; X Wu; W Chan; M A Pershouse; W K Yung; P A Steck
Journal:  Clin Cancer Res       Date:  1998-10       Impact factor: 12.531

8.  Long-term glioblastoma multiforme survivors: a population-based study.

Authors:  J N Scott; N B Rewcastle; P M Brasher; D Fulton; N A Hagen; J A MacKinnon; G Sutherland; J G Cairncross; P Forsyth
Journal:  Can J Neurol Sci       Date:  1998-08       Impact factor: 2.104

9.  Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas.

Authors:  J G Cairncross; K Ueki; M C Zlatescu; D K Lisle; D M Finkelstein; R R Hammond; J S Silver; P C Stark; D R Macdonald; Y Ino; D A Ramsay; D N Louis
Journal:  J Natl Cancer Inst       Date:  1998-10-07       Impact factor: 13.506

10.  Prognostic significance of p53 immunoreactivity in patients with glioma.

Authors:  A P Kyritsis; M L Bondy; K R Hess; J E Cunningham; D Zhu; C J Amos; W K Yung; V A Levin; J M Bruner
Journal:  Clin Cancer Res       Date:  1995-12       Impact factor: 12.531

View more
  32 in total

1.  {Beta}2-adrenergic receptor agonists inhibit the proliferation of 1321N1 astrocytoma cells.

Authors:  L Toll; L Jimenez; N Waleh; K Jozwiak; A Y-H Woo; R-P Xiao; M Bernier; I W Wainer
Journal:  J Pharmacol Exp Ther       Date:  2010-11-11       Impact factor: 4.030

2.  CD8+ T-cell infiltrate in newly diagnosed glioblastoma is associated with long-term survival.

Authors:  Isaac Yang; Tarik Tihan; Seunggu J Han; Margaret R Wrensch; John Wiencke; Michael E Sughrue; Andrew T Parsa
Journal:  J Clin Neurosci       Date:  2010-08-19       Impact factor: 1.961

3.  Prospective analysis of incidence of central nervous tumors presenting in a tertiary cancer hospital from India.

Authors:  Rakesh Jalali; Debnarayan Datta
Journal:  J Neurooncol       Date:  2007-11-15       Impact factor: 4.130

4.  Adult glioblastoma multiforme survival in the temozolomide era: a population-based analysis of Surveillance, Epidemiology, and End Results registries.

Authors:  Amy S Darefsky; Joseph T King; Robert Dubrow
Journal:  Cancer       Date:  2011-08-31       Impact factor: 6.860

5.  Treatment and survival of glioblastoma patients in Denmark: The Danish Neuro-Oncology Registry 2009-2014.

Authors:  Steinbjørn Hansen; Birthe Krogh Rasmussen; René Johannes Laursen; Michael Kosteljanetz; Henrik Schultz; Bente Mertz Nørgård; Rikke Guldberg; Kim Oren Gradel
Journal:  J Neurooncol       Date:  2018-05-12       Impact factor: 4.130

Review 6.  Associations of social networks with cancer mortality: a meta-analysis.

Authors:  Martin Pinquart; Paul R Duberstein
Journal:  Crit Rev Oncol Hematol       Date:  2009-07-14       Impact factor: 6.312

7.  Improved survival for elderly married glioblastoma patients : Better treatment delivery, less toxicity, and fewer disease complications.

Authors:  Florian Putz; Tobias Putz; Nicole Goerig; Stefan Knippen; Thomas Gryc; Ilker Eyüpoglu; Karl Rössler; Sabine Semrau; Sebastian Lettmaier; Rainer Fietkau
Journal:  Strahlenther Onkol       Date:  2016-09-14       Impact factor: 3.621

8.  Daily intake of antioxidants in relation to survival among adult patients diagnosed with malignant glioma.

Authors:  Gerald N DeLorenze; Lucie McCoy; Ai-Lin Tsai; Charles P Quesenberry; Terri Rice; Dora Il'yasova; Margaret Wrensch
Journal:  BMC Cancer       Date:  2010-05-19       Impact factor: 4.430

9.  Prognostic significance of growth kinetics in newly diagnosed glioblastomas revealed by combining serial imaging with a novel biomathematical model.

Authors:  Christina H Wang; Jason K Rockhill; Maciej Mrugala; Danielle L Peacock; Albert Lai; Katy Jusenius; Joanna M Wardlaw; Timothy Cloughesy; Alexander M Spence; Russ Rockne; Ellsworth C Alvord; Kristin R Swanson
Journal:  Cancer Res       Date:  2009-11-24       Impact factor: 12.701

10.  Disparities in receipt of modern concurrent chemoradiotherapy in glioblastoma.

Authors:  Ryan Rhome; Rebecca Fisher; Adília Hormigo; Rahul R Parikh
Journal:  J Neurooncol       Date:  2016-03-12       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.